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ABSTRACT
OBJECTIVE: To describe urinary tract infection (UTI) treatment among Veterans Affairs
(VA) Community Living Centers (CLCs) nationally and assess trends in antibiotic use.
DESIGN: Descriptive study.
SETTING AND PARTICIPANTS: All UTI episodes treated from 2013-2017 among
residents in 110 VA CLCs. UTI episodes required collection of a urine culture, antibiotic
treatment, and a UTI diagnosis code. UTI episodes were stratified into culture-positive
and negative.
METHODS: Frequency and rate of antibiotic use were assessed for all UTI episodes
overall and stratified by culture-positive and negative episodes. Joinpoint Software was
used for regression analyses of trends over time.
RESULTS: We identified 28,247 UTI episodes in 14,983 Veterans. The average age of
Veterans was 75.7 and 95.9% were male. About half (45.7%) of UTI episodes were
culture-positive and 25.7% were culture-negative. Escherichia coli was recovered in
34.1% of culture-positive UTI episodes, followed by Proteus mirabilis and Klebsiella
recovered in 24.5% and 17.4% of culture-positive UTI episodes, respectively. The rate
of total antibiotic use in DOT/1,000 bed days decreased by 10.1% per year (95% CI 13.6 - -6.5%) and fluoroquinolone use (ciprofloxacin or levofloxacin) decreased by
14.5% per year (95% CI -20.6 - -7.8%) among UTI episodes overall. Similar reductions
in rates of total antibiotic use and fluoroquinolone use were observed among culturepositive and among culture-negative UTI episodes.
CONCLUSION:
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Over a 5-year period, antibiotic use for UTIs significantly decreased among VA CLCs,
as did use of fluoroquinolones. Antibiotic stewardship efforts across VA CLCs should be
applauded and continue to be an ongoing effort.
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TEXT
BACKGROUND
Antibiotics are among the most frequently used medications in long-term care facilities
(LTCFs), however up to 75% of antibiotic use in LTCFs may be inappropriate.1,2 The
greatest contributor to inappropriate antibiotic use in LTCFs is the misuse of antibiotics
for urinary tract infections (UTIs).2-7 The most common problem in the treatment of UTIs
among residents is misdiagnosis and treatment of asymptomatic bacteriuria with
antibiotics.8 Another common problem is the use of agents that are overly broadspectrum or carry an increased risk of adverse drug events, such as fluoroquinolones.9
Data from 2010 and more recent data from 2014-2016 demonstrate that
fluoroquinolones are the most commonly used agents used for treatment of UTI among
LTCF residents.9-11 This has been in spite of recommendations specific to LTCF
residents which call for restricted use of fluoroquinolones due to their risk for Clostridium
difficile infection, adverse drug events, and selection of resistance since 2000.12,13 Per
2004 and 2011 treatment guidelines of the Infectious Diseases Society of America
(IDSA), labeled warnings from the Food and Drug Administration, and expert opinion,
fluoroquinolones should only be used for the treatment of acute cystitis when other UTI
antibiotics cannot be used due to their propensity for collateral damage.14-16

While previous research suggests that antibiotic selection for UTIs may often be
suboptimal, large-scale studies of how LTCF residents are treated for UTIs nationally
are limited. Quantifying how UTIs are treated is a first step in improving the use of
antibiotics.17 Knowledge of the most commonly used antibiotic agents and the trends in
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use can inform future efforts to optimize antibiotic use among LTCF residents nationally.
Such data can also identify problem areas, allowing the development of targeted
interventions to improve antibiotic use, ultimately improving the care of residents with
UTIs. As such, the aim of this work was to describe antibiotic use for UTI among all VA
LTCFs (known as Community Living Centers or CLCs) nationally from 2013 to 2017 and
assess trends in antibiotic use.

METHODS
We conducted a retrospective study using national VA microbiology and pharmacy data
accessed through the VA Informatics and Computing Infrastructure (VINCI). We
included all adult (age >18 years) residents with a UTI episode during an inpatient stay
in a VA CLC unit between January 2013 to December 2017. Three inclusion criteria
were applied to identify episodes of UTI: (1) collection of urine culture, (2) initiation of a
UTI-related antibiotic on the date the urine culture was taken or within the 3 days after
culture collection, and (3) a diagnosis code for UTI (International Classification of
Diseases, 9th or 10th edition).18

We excluded episodes that likely represented treatment of asymptomatic bacteriuria for
urologic procedure or pregnancy.19 Urologic procedures (e.g. transurethral resection of
the prostate, prostate biopsy, cycstoscopy, urodynamic surgery) were identified using
previously reported diagnosis and procedure codes and using text searches of
procedure names.20,21 All residents with a urologic produce that occurred within 2 weeks
of the date of the index urine culture were excluded. We also excluded women of
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childbearing age (females < 45 years at the time of urine culture). To avoid capturing
treatment of another potential infection, we excluded episodes in which another positive
culture (i.e. blood, respiratory, tissue, bone) was identified within 3 days of the index
culture, unless it was a positive blood culture for the same organism growing in the
urine.22 In the case of multiple UTI episodes during the study period, we excluded
subsequent UTI episodes within 30 days of the first episode.

UTI episodes were stratified by urine culture results into culture-negative, culturepositive, and other episodes. Culture-negative UTI episodes were those in which no
growth was identified from the urine culture. Culture-positive UTI episodes were defined
as those in which no more than two typical uropathogens (Escherichia coli, Proteus
mirabilis, Klebsiella species [spp], Pseudomonas aeruginosa, Providencia spp,
Enterobacter spp, Citrobacter spp., Morganella morganii, Serratia marcescens,
Enterococcus spp, Staphylococcus aureus) were isolated with quantitative counts > 105
CFU/mL from the urine culture.14,19,23,24 Uropathogens of interest were chosen based on
earlier work indicating these were the most frequently isolated organisms from urine
samples obtained from LTCF residents.25 All other UTI episodes were defined as those
in which typical uropathogens were isolated with low quantitative counts (< 105
CFU/mL), more than two uropathogens were identified, or any other organisms were
isolated from the urine culture.

We quantified the frequency and rate of antibiotic use for all UTI episodes overall and
stratified by culture-positive and culture-negative UTI episodes. Frequency of use was
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the proportion of the number UTI episodes treated with a specific antibiotic agent/class
divided by the total number of UTI episodes that met study criteria as defined above.
The rate of antibiotic use was defined as antibiotic days of therapy (DOT).22 One DOT
represents administration of a single agent on a given day regardless of frequency,
dose, or route of administration. For each UTI episode, we calculated the DOT for each
antibiotic used from the start to the end of the treatment up to 30-days post-treatment
start. End of treatment was identified from gaps in antibiotic therapy of more than 2
consecutive calendar days.

We summed all UTI specific antibiotic use for our study cohort and standardized it to
1,000 bed days of care (DOT/1,000 bed days). Antibiotics were grouped into the
following classes: typical genitourinary tract agents (nitrofurantoin, sulfamethoxazole/
trimethoprim, fosfomycin, trimethoprim), fluoroquinolones (ciprofloxacin, levofloxacin),
1st-2nd generation cephalosporins (cefaclor, cefazolin, cefotetan, cefoxitin, cefuroxime,
cephalexin), 3rd-4th generation cephalosporins (cefdinir, cefepime, cefixime, cefotaxime,
cefpodoxime, ceftazidime, ceftriaxone), aminopenicillins (amoxicillin, ampicillin,
amoxicillin/clavulanate, amipicillin/sulbactam), carbapenems and piperacillin/
tazobactam (imipenem, meropenem, ertapenem, doripenem, piperacillin/ tazobactam),
other multidrug resistant [MDR] gram-negative agents (amikacin, gentamicin,
tobramycin, avibactam/ceftazidime, aztreonam, ceftazidime\avibactam, tigecycline),
anti-methicillin resistant Staphylococcus aureus [MRSA] directed agents (ceftaroline,
daptomycin, linezolid, vancomycin), and other agents.
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We identified time trends over the study period using joinpoint regression models. The
Joinpoint Regression Program version 4.6.0.0 (National Cancer Institute, Bethesda,
MD, USA) was used to calculate average annual percent change (AAPC) and 95%
confidence intervals (CI).26 Significance was set at p<0.05. The AAPC is a weighted
average of the average percent change (APC) segments from a joinpoint model with the
weights equal to the duration of each APC segment.

RESULTS
We identified a total of 28,247 UTI episodes diagnosed and treated with antibiotics
within 3 days of urine culture among 14,983 Veterans admitted to 110 VA CLCs
nationally. The median number of UTI episodes per Veteran was 1.0 (interquartile range
[IQR] 1-2) and the median length of stay among unique Veteran admissions (n=15,829)
was 127 days (IQR 43-717). At the time of the first UTI episode, the average age of
Veterans was 75.7 years (+/- 11.5 standard deviation) and 95.9% (n=14,363) were
male. Additional baseline characteristics are presented in Table 1.

Urine culture results are presented in Table 2. Approximately half of UTI episodes were
culture-positive (n=12,905, 45.7%) and 25.7% (n=7,265) were culture-negative.
Escherichia coli was recovered in 34.1% (n=4,400) of culture-positive UTI episodes,
followed by Proteus mirabilis and Klebsiella spp. recovered in 24.5% (n=3,160) and
17.4% (n=2,244) of culture-positive UTI episodes, respectively.

9

Among all UTI episodes, the most frequently used antibiotic agents were ciprofloxacin
(31.2%, n=8,818), sulfamethoxazole/trimethoprim (20.9%, n=5,908), and ceftriaxone
(16.3%, n=4,591, Table 3). Ciprofloxacin, sulfamethoxazole/trimethoprim, and
ceftriaxone also had the greatest usage in DOT, accounting for 19.4% (DOT=57,579),
14.6% (DOT=43,244), and 8.2% (n=24,231) of the total DOT used, respectively. Use of
broad-spectrum intravenous antibiotic agents accounted for approximately 20% of the
total DOT used. The rate of total antibiotic use decreased significantly by 10.1% per
year (95% CI -13.6 – -6.5%) from 20.7 DOT/1,000 bed days in 2013 to 13.2 DOT/1,000
bed days in 2017. The rate of fluoroquinolone (ciprofloxacin and levofloxacin) use in
DOT/1,000 bed days decreased significantly by 14.5% per year (95% CI -20.6 – -7.8%).
The proportion of UTI episodes treated with fluoroquinolones decreased significantly by
6.0% per year (95% CI -10.4 – -1.3%) over the study period. Fluoroquinolones were
used in 44.2% (n=2,958/6,693) of suspected UTI episodes in 2013 and in 35.2% of
episodes in 2017 (n=1,645/4,675).

Among culture-positive UTI episodes, ciprofloxacin (33.5%, n=4,323),
sulfamethoxazole/ trimethoprim (23.4%, n=3,015), and ceftriaxone (16.7%, n=2,149)
remained the most frequently used antibiotic agents. Several significant changes in the
rate of antibiotic use for culture-positive UTI episodes were observed (Figure 1). The
rate of total antibiotic use for culture-positive episodes decreased significantly by 9.6%
per year (95% CI -13.1 – -6.0%). The rate of fluoroquinolone use decreased significantly
by 14.9% per year (95% CI -22.0 – -7.3%).
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Among culture-negative UTI episodes, ciprofloxacin (26.1%, n=1,899),
sulfamethoxazole/ trimethoprim (16.6%, n=1,203), and ceftriaxone (16.1%, n=1,167)
also remained the most frequently used antibiotic agents. Among culture-negative UTI
episodes, 19,376 fluoroquinolone DOT were used, accounting for 25.4% of all
fluoroquinolone use (DOT=76,162). Trends in antibiotic use for culture-negative UTI
episodes are presented in Figure 2. Significant reductions in the rates of total antibiotic
use (by 11.2% per year, 95% CI -14.8 – -7.4%) and fluoroquinolone use (by 14.8% per
year, 95% CI -19.6 – -9.7%) were observed.

DISCUSSION
In our study of about 15,000 Veterans diagnosed and treated for UTIs in CLCs
nationally, fluoroquinolone use decreased, as did overall antibiotic days of therapy.
Results stratified by culture-positive and culture-negative UTI episodes were similar.

Ciprofloxacin, sulfamethoxazole/trimethoprim, and ceftriaxone were the most commonly
used antibiotic agents. Previous work among Veteran cohorts from outpatient and acute
care inpatient settings have also found that these agents are among the most
commonly used antibiotics for UTI.27,28 Data from non-VA LTCFs has similarly identified
fluoroquinolones as the most commonly used antibiotic class for UTIs.9-11

As expected, the typical uropathogens, including E. coli, Proteus, and Klebsiella spp.,
were the most commonly identified uropathogens among culture-positive UTI
episodes.31 Similar to our findings, E. coli was the most common (53.6%) organism
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identified among 240 episodes of UTI among residents in 5 Connecticut LTCF, followed
by Proteus spp (14.6%) and Klebsiella spp (13.9%).25 About 25% of the UTI episodes in
our study were culture-negative, and suggest potential overtreatment. Previous work
has confirmed the overtreatment of UTI, in both the presence and absence of positive
urine cultures, among older adults without symptoms of a UTI. In a study of 153 older
women diagnosed with a UTI, only 87 (57%) had microbiological evidence of a UTI, yet
95% of the 66 patients with negative cultures received antibiotics.32

While our work does suggest potential overtreatment, our work also demonstrated
several impressive reductions in the use of antibiotics for UTI in VA CLCs nationally. We
found that total antibiotic use decreased by approximately 10% per year from 2013 to
2017 for all UTI episodes, and by 10% among culture-positive episodes and 11%
among culture-negative episodes. Improving the diagnosis and treatment of UTIs is a
well-recognized antibiotic stewardship target among LTCFs.33 Among VA medical
centers, previous work has confirmed an increase antibiotic stewardship over the study
period.34 However, there may be facility level or regional variation in application of
antibiotic stewardship principles, which warrant future investigation. Previous work has
demonstrated variation in antibiotic use at the facility and regional levels in non-VA
LTCFs and in VA facilities.35-37

Another encouraging trend we observed was the decrease in fluoroquinolone use
among all UTI episodes overall and stratified by culture-positive and culture-negative
episodes. Overall the proportion of UTI episodes treated with fluoroquinolones
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decreased by 6.0% each year, as did the rate of fluoroquinolones use (by 14.5%).
Reductions in use may be related to growing evidence on fluoroquinolone-related
adverse effects, especially in older patients.16,38 In 2008, a boxed warning for an
increased risk of tendinitis and tendon rupture with fluoroquinolones was mandated by
the Food and Drug Administration (FDA). Since that time, the FDA has issued warnings
for other serious adverse effects, including exacerbation of myasthenia gravis, C.
difficile infection, QT-interval prolongation, severe hypoglycemia, and mental health
effects.38 In 2013 the FDA updated label warnings for fluoroquinolones and in 2016 the
FDA specifically recommended use of fluoroquinolones be avoided for uncomplicated
UTIs, unless no alternative treatment options were available.16 Nitrofurantoin and
sulfamethoxazole/trimethoprim are suggested empiric UTI treatment options for older
patients without complicated coexisting conditions and mild UTI symptoms.13,41,42
However, nitrofurantoin should be avoided in patients with pyelonephritis or a history of
UTI due to P. mirabilis. Given the high prevalence of P. mirabilis we observed across
VA nursing homes nationally, our results suggest avoidance of nitrofurantoin as empiric
therapy, however local resistance patterns should guide empiric therapy. Nitrofurantoin
may be an option once urine culture results are available.

While fluoroquinolone use decreased over the study period, our results demonstrated
that fluoroquinolones are still a preferred treatment choice. Fluoroquinolones
remained the most frequently used antibiotic class for UTIs over the entire study period,
even in 2017 (35.5% of episodes). These findings may be related to our complicated
study population of mostly older male Veterans. All urinary tract infections in males are
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generally considered complicated.19,23 Moreover, approximately 45% of Veterans in our
study had comorbid benign prostatic hyperplasia, which may lead to complicated UTIs
and prostatitis due to obstructed and turbulent urine flow.39 Fluoroquinolones achieve
reliable tissue concentrations in the prostate and are considered first-line in men with
severe UTI symptoms or concern for prostate involvement.39 While our findings do
demonstrate impressive reductions in fluoroquinolone use for UTIs among VA CLCs
nationally, there may be room for further improvement in reducing fluoroquinolone use.
Focused antibiotic stewardship efforts to further fluoroquinolone use which have been
successful in single center studies include the removal of fluoroquinolones from local
formularies and order sets.40,41 Overall, about 76,000 fluoroquinolone DOT were used
over our study period, and 25% of that use was for culture-negative UTI episodes. Thus,
negative cultures may be an easy target for antibiotic stewardship in CLCs to further
reduce fluoroquinolone use in residents who do not have symptoms of urinary infection.

There are limitations to this retrospective study. We defined UTIs as a urine culture plus
antibiotic treatment in the presence of a UTI diagnosis code. We were unable to capture
treatment practices for UTIs in which no cultures were obtained, that were culturepositive and treated without a UTI diagnosis code, or that were treated outside the VA
CLC setting. We assumed that antibiotic administrations were intended for the treatment
of a UTI, since antibiotic indication is often missing. To minimize the possibility of
treatment for anther infection type, we excluded UTI episodes in which there were
concomitant positive cultures from other sources and required a diagnosis code for UTI.
Another limitation is we were interested in the real-world treatment of UTIs, we did not
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attempt to distinguish treatment of asymptomatic bacteriuria versus truly symptomatic
UTI. We did attempt to exclude asymptomatic bacteriuria in the presence of urologic
procedure or pregnancy. Additionally, we were unable to capture urinary catheter use
and thus unable to quantify the prevalence of caterer use in our population. It is possible
that catheter use declined over the study period and may account in part for the
observed decreases in antibiotic use. Finally, the generalizability of our findings to other
populations may be limited, as our population is predominantly male.

In conclusion, our study of over 28,000 UTI episodes in VA CLCs nationally
demonstrated a decrease in overall antibiotic use for UTIs, including the use of
fluoroquinolone antibiotics. Antibiotic stewardship efforts across VA CLCs should be
applauded and should continue to be an ongoing effort, especially in reducing the
overtreatment of UTI, in both the presence and absence of positive urine cultures, in
patients without urinary symptoms.
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Table 1. Baseline characteristics of Veterans admitted to VA nursing homes
nationally with treated urinary tract infection
Characteristic

Number

Percent

Age in years (mean, standard deviation)a

75.7

11.5

Male gender

14,363

95.9

Hypertension

11,399

76.1

Dementia

9,076

60.6

Diabetes

7,143

47.7

Benign prostatic hyperplasia

6,791

45.3

Atherosclerosis

6,467

43.2

Nutritional deficiencies

6,370

42.5

Chronic respiratory disease

6,124

40.9

Congestive heart failure

4,980

33.2

Chronic renal disease

5,069

33.8

Complication of device, implant or graftb

2,587

17.3

Adverse effects of medical carec

1,681

11.2

Demographics

Comorbidities

Data are presented as the number and percent, unless otherwise indicated.
Characteristics presented for 14,983 unique Veterans at the time of the first UTI episode
included over the study period.
a Age

measured at time of urine culture collection
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b Includes

breakdown, leakage, or complication of urinary catheter

c Includes

all misadventures to patients during surgical or medical care, medical devices

associated with adverse incidents in diagnostic and therapeutic use, and surgical or
medical care causing abnormal reaction or complication to the patient, such as urinary
catherization as a cause of complication.
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Table 2. Urine culture results obtained from 28,247 episodes of urinary tract
infections in VA Community Living Centers nationally, 2013 to 2017
Organism

Frequency (n)

Percent (%)

Culture-positive

12,905

45.7

Escherichia coli

4,400

34.1

Proteus mirabilis

3,160

24.5

Klebsiella spp.

2,244

17.4

Pseudomonas aeruginosa

1,136

8.8

Providencia spp.

526

4.1

Enterobacter spp.

404

3.1

Citrobacter spp.

305

2.4

Morganella morganii

300

2.3

Serratia marcescens

126

1.0

Enterococcus spp.

1,403

10.9

Staphylococcus aureus

594

4.6

Culture-negative

7,265

25.7

Other

8,077

28.6

Spp= species
Culture-positive UTI episodes were defined as those in which no more than two typical
uropathogens were isolated with quantitative counts > 105 CFU/mL from the urine
culture.

26

Culture-negative UTI episodes were those in which no growth was identified from the
urine culture.
All other UTI episodes were defined as those in which typical uropathogens were
isolated with low quantitative counts (< 105 CFU/mL), more than two uropathogens were
identified, or any other organisms were isolated from the urine culture.
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Table 3. Antibiotic use by agent for urinary tract infections in VA Community
Living Centers nationally, 2013 to 2017
Percent of
Antibiotic use

total

Percent of

in days of

antibiotic

Frequency

total UTI

Antibiotic agent

therapy (DOT)

use (%)

of use (n)

episodes (%)

Ciprofloxacin

57,579

19.4

8,818

31.2

Trimethoprim

43,244

14.6

5,908

20.9

Ceftriaxone

24,231

8.2

4,591

16.3

clavulanate

22,873

7.7

3,161

11.2

Cephalexin

18,855

6.4

2,566

9.1

Levofloxacin

18,583

6.3

3,179

11.3

tazobactam

17,659

6.0

2,983

10.6

Nitrofurantoin

15,222

5.1

1,953

6.9

Cefpodoxime

9,431

3.2

1,242

4.4

Vancomycin

8,312

2.8

1,120

4.0

Amoxicillin

7,849

2.7

1,036

3.7

Cefepime

7,711

2.6

1,200

4.2

Ertapenem

7,487

2.5

934

3.3

Cefuroxime

7,326

2.5

934

3.3

Sulfamethoxazole/

Amoxicillin/

Piperacillin/
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Exposure in
<2% of total
Other agents

-

DOT

<2% of UTI
-

episodes
28,247 UTI

Total

296,176 DOT

episodes

DOT= Days of therapy; UTI= Urinary tract infection
Frequency of antibiotic use is not mutually exclusive, as UTI episodes could be treated
with more than one antibiotic.
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Figure 1. Trends in rate of antibiotic use among culture-positive urinary tract
infections in VA Community Living Centers nationally, 2013 to 2017
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AAPC= average annual percent change; CI=confidence interval; UTI= urinary tract
infection; MDR= Multidrug resistant; MRSA= methicillin resistant Staphylococcus aureus
AAPCs represent the average percent change per year in rate of antibiotic use in DOT
per 1,000 bed days; *=Significant trend at p<0.05
Solid blue columns represent the rate of antibiotic use per year in DOT per 1,000 bed
days (range 9.4 to 6.2 DOT/1,000 bed days)
Lines with markers represent the rate of antibiotic use by class per year in DOT per
1,000 bed days
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Figure 2. Trends in rate of antibiotic use among culture-negative urinary tract
infections in VA Community Living Centers nationally, 2013 to 2017
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AAPC= average annual percent change; CI=confidence interval; DOT= Days of therapy;
UTI= urinary tract infection; MDR= Multidrug resistant

AAPCs represent the average percent change per year in rate of antibiotic use in DOT
per 1,000 bed days; *=Significant trend at p<0.05
Solid blue columns represent the rate of all antibiotic use per year in DOT per 1,000 bed
days (range 4.8 to 2.9 DOT/1,000 bed days)
Lines with markers represent the rate of antibiotic use by class per year in DOT per
1,000 bed days
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